Coulter Partners is a board and senior level global executive search specialist focused exclusively on Life Sciences. We work closely with those at the cutting edge of innovation in the industry to understand their challenges. With an extensive global network and expertise gained over 25 years in the sector, we have become trusted advisers on leadership in the pharmaceuticals, biotechnology, medical technology, diagnostics, health tech, CRO and services sectors. We also work closely with the global investor community, hiring for their own teams as well as building the boards and executive leadership teams of their portfolio companies. The largest and fastest growing dedicated Life Science search firm, our team of 95 completes over 260 assignments a year working from 14 offices across UK, EMEA, USA & APAC. We share knowledge and connections across the globe, as one team with one goal. To bring our clients the world’s best talent.
At the heart of everything they do Coulter Partners is an exceptional team of talented individuals. Multi-disciplined, passionate and committed to being the best, they have PhDs, MBAs and speak many languages. Every challenge is approached with a blend of innovative thinking and best-in-class search methodology. There are no barriers to sharing information and everyone is rewarded for quality delivery. Exchanging knowledge, experience and data brings mutual support. Success follows naturally.
Coulter Partners is a global search specialist focused exclusively on life sciences. The firm is held in the highest regard as trusted adviser to the sector on senior leadership roles in the American, U.K. and European Markets.
Life sciences search specialist Coulter Partners has placed Walter Miller as chief finance officer and Charles Woler as non-executive director of Optimapharm. Directors Mark Sharp and Irene Montgomery led the assignment. “It has been a privilege to partner with Optimapharm on two more key search assignments, following our collaboration to bring Andrew Copestake on board as CEO
Life sciences search specialist Coulter Partners has placed Brian O’Callaghan as chief executive officer of ObsEva, a clinical-stage biopharmaceutical company developing and commercializing novel therapies for women’s reproductive health. Client partner Nona Footz led the assignment. Mr. O’Callaghan succeeds Ernest Loumaye, who co-founded the firm in 2012. As ObsEva evolves from a development company toward
Life sciences search specialist Coulter Partners has formed a partnership with BioInnovation Institute (BII), the international incubator in Denmark for research-based innovation and entrepreneurship. The firm has been engaged to provide support for BII across three workstreams: providing assessment, coaching and development for the CEOs of start-up businesses in BII’s portfolio under the Creation House
The demand for talent in the life sciences sector has fueled continued growth at global executive search firm Coulter Partners. In many ways, the global pandemic has expanded the need for skilled leaders across the sector. To help manage its growth, the firm recently hired Marianne McNamara as operations director for the U.S. Also joining
(April 2021) Coulter Partners was very pleased to partner recently with OxSonics® Therapeutics, a world leader in the development of ultrasound-based drug delivery systems for the treatment of cancer, to secure the appointment of Dr Allison Jeynes as non-executive Chair of the Board of Directors. Dr Allison Jeynes, MD, FFPM (UK), is a trained clinician
(March 2021) Global Life Sciences executive search specialist, Coulter Partners is delighted to announce continuing growth across the company in 2021. The London team expands with new Associates, Lucy Webb and Ana Delgado, Research Analysts, Jacob Taylor and Liam Fryer, and Director, Carina McEntire. In the US, Ayn Teigman is appointed Associate in New York
(March 1, 2021) Coulter Partners was delighted to partner again recently with Optimapharm to secure the appointments of Walter Miller as Chief Finance Officer and Dr Charles Woler, M.D., Ph.D., as Non-Executive Director. Optimapharm is a contract research organization (CRO) managing clinical trials on behalf of leading biotech, pharma and medical devices companies in 27
(Aug. 27, 2020) Coulter Partners was very pleased to partner once again with Saniona (OMX: SANION), a clinical stage biopharmaceutical company focused on rare diseases, to secure the appointment of Jason A. Amello as Chief Financial Officer. Jason will be based in the U.S. and will support Saniona’s advancement of late-stage clinical trials with lead
(Aug. 20, 2020) Coulter Partners was very pleased to partner recently with Sequana Medical NV (Euronext Brussels: SEQUA), an innovator in the management of fluid overload in liver disease, malignant ascites and heart failure, to secure the appointment of Oliver Gödje, MD, PhD, as Chief Medical Officer. Dr Gödje replaces Gijs Klarenbeek, MD, who remains